Clearance kinetics of a hylan-based viscosupplement after intra-articular and intravenous administration in animal models

Journal of Biomedical Materials Research - Part B Applied Biomaterials

Volumn 100 B, Issue 2, 2012, Pages 457-462

  Larsen, Nancy E ^a   Dursema, Holly D ^a   Pollak, Cynthia T ^a   Skrabut, Eugene M ^a  

^a Genzyme Biosurgery   (United States)

Author keywords

hyaluronan; hylan G F 20; osteoarthritis; Synvisc; viscosupplementation

Indexed keywords

HYALURONAN; HYLAN G-F 20; OSTEOARTHRITIS; SYNVISC; VISCOSUPPLEMENTATION;

BLOOD; DEGRADATION; FLUIDS; GELS; RADIATION; RADIOACTIVITY; TISSUE;

JOINTS (ANATOMY);

HYALURONIC ACID; HYLAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DEGRADATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; GEL; ISOTOPE LABELING; JOINT; KIDNEY; LIVER; LUNG; LYMPH NODE; MALE; MOLECULAR WEIGHT; NONHUMAN; POPLITEAL LYMPH NODE; QUANTITATIVE ANALYSIS; RABBIT; RADIOACTIVITY; SPLEEN; SYNOVIAL FLUID; TREATMENT OUTCOME; VISCOSUPPLEMENTATION; ANALOGS AND DERIVATIVES; ANIMAL; INTRAARTICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KINETICS; METABOLISM; OSTEOARTHRITIS, KNEE; PATHOLOGY; RAT;

ADMINISTRATION, INTRAVENOUS; ANIMALS; HYALURONIC ACID; INJECTIONS, INTRA-ARTICULAR; KINETICS; MALE; OSTEOARTHRITIS, KNEE; RABBITS; RATS;

EID: 84855450480     PISSN: 15524973     EISSN: 15524981     Source Type: Journal    
DOI: 10.1002/jbm.b.31971     Document Type: Article

References (35)

1. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum, 2000; 43: 1905-1915.
2. Balazs E, Briller S, Denlinger JL, Na-hyaluronate molecular size variations in equine and human arthritic synovial fluid and effect on phagocytic cells. Semin Arthritis Rheum 1981; 11: 141-143. (Pubitemid 11009740)
3. Schurz J, Ribitsch, V., Rheology of synovial fluid. Biorheology 1987; 24: 385-399. (Pubitemid 17152533)
4. Mazzucco D, McKinley G, Scott RD, Spector M,. Rheology of joint fluid in total knee arthroplasty patients. J Orthop Res 2002; 20: 1157-1163. (Pubitemid 35363971)
5. Balazs EA, Cowman MK, Goldman AI, Band PA, Lee HG, Moreland L,. Correlation of knee pain with synovial fluid properties in osteoarthritis patients. In New Frontiers in Medical Science:Redefining Hyaluronan. Consorzio Tissuetech: Padua, Italy; 1999.
6. Balazs E, Denlinger, J., Sodium hyaluronate and joint function. J Equine Vet Sci 1985: 217-228.
7. Phillips M,. Clinical trial comparison of intra-articular sodium hyaluronate products in the horse. J Equine Vet Sci 1989: 39-40.
8. Lentner C, editor. Geigy Scientific Tables: Units of Measurement, Body fluids, Composition of the Body, Nutrition, in Medical Education Division, Ciba-Geigy Corp., CIBA-GEIGY: West Caldwell, NJ; 1981.
9. Balazs EA,. The physical properties of synovial fluid and the special role of hyaluronic acid. In:, Helfet A, editor. Disorders of the Knee, 2nd ed. Philadelphia: Lipinscott Company; 1982.
10. Myers RR, Nagami S, White RK,. Dynamic mechanical properties of synovial fluid. Biorheology 1966: 197-209.
11. Levick JR, McDonald JN,. Fluid movement across synovium in healthy joints: Role of synovial fluid macromolecules. Ann Rheum Dis 1995; 54: 417-423.
12. Coleman PJ, Scott D, Mason RM, Levick JR,. Role of hyaluronan chain length in buffering interstitial flow across synovium in rabbits. J Physiol 2000; 526 (Pt 2): 425-434. (Pubitemid 30599292)
13. Brown TJ, Laurent UB, Fraser JR,. Turnover of hyaluronan in synovial joints: elimination of labelled hyaluronan from the knee joint of the rabbit. Exp Physiol 1991; 76: 125-134.
14. Fraser JR, Kimpton WG, Pierscionek BK, Cahill RN,. The kinetics of hyaluronan in normal and acutely inflamed synovial joints: observations with experimental arthritis in sheep. Semin Arthritis Rheum 1993; 22 (Suppl 1): 9-17. (Pubitemid 23176279)
15. Denlinger J,. Metabolism of sodium hyaluronate in articular and ocular tissues. Ph.D. Thesis, University of Lille, France, 1982.
16. Antonas KN, Fraser JR, Muirden KD,. Distribution of biologically labelled radioactive hyaluronic acid injected into joints. Ann Rheum Dis 1973; 32: 103-111.
17. Fraser JR, Kimpton WG, Laurent TC, Cahill RN, Vakakis N,. Uptake and degradation of hyaluronan in lymphatic tissue. Biochem J 1988; 256: 153-158.
18. Laurent TC, Fraser JRE, Catabolism of hyaluronan. In: Degradation of Bioactive Substances: Physiology and Pathaphysiology., Henriksen J, editor. Boca Raton, FL: CRC Press; 1991.
19. Fraser JR, Laurent TC,. Turnover and metabolism of hyaluronan. Ciba Found Symp 1989; 143: 41-53.
20. Fraser JR, Laurent TC, Pertoft H, Baxter E,. Plasma clearance, tissue distribution and metabolism of hyaluronic acid injected intravenously in the rabbit. Biochem J 1981; 200: 415-424. (Pubitemid 12218264)
21. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G,. Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2006: CD005321.
22. Conrozier T, Jerosch J, Beks P, Kemper F, Euller-Ziegler L, Bailleul F, Chevalier X,. Prospective, multi-centre, randomised evaluation of the safety and efficacy of five dosing regimens of viscosupplementation with hylan G-F 20 in patients with symptomatic tibio-femoral osteoarthritis: a pilot study. Arch Orthop Trauma Surg 2009; 129: 417-423.
23. Chevalier X, Jerosch J, Goupille P, van Dijk N, Luyten FP, Scott DL, Bailleul F, Pavelka K,. Single, intra-articular treatment with 6 ml hylan G-F 20 in patients with symptomatic primary osteoarthritis of the knee: A randomised, multicentre, double-blind, placebo controlled trial. Ann Rheum Dis 2010; 69: 113-119.
24. Frampton JE,. Hylan G-F 20 single-injection formulation. Drugs Aging 2010; 27: 77-85.
25. Genzyme. Complete Prescribing Information for Synvisc-One. Available at:, accessed March 19, 2009 Instruction for use.
26. Balazs E, Leshchiner A, Leshchiner A, Larsen N, Band P,. Hylan preparation and method of recovery thereof from animal tissues., U.S.P.a.T. Office, Editor. U.S. Patent 5099013 (1992).
27. Balazs E, Leshchiner A,. Cross linked gels of hyaluronic acid and products containing such gels, U.S.P.a.T. Office, Editor. U.S. Patent 4636524 (1987).
28. Larsen NE, Pollak CT, Reiner K, Leshchiner E, Balazs EA,. Hylan gel biomaterial: Dermal and immunologic compatibility. J Biomed Mater Res 1993; 27: 1129-1134. (Pubitemid 23241076)
29. Jones J,. Rates of detritiation of various carbon acids in water-hydroxide and alcohol-alkoxide media: a possible probe for classfication of carbon acid. J Phys Chem 1989: 1362-1365.
30. Chang G, Boney J, Konowicz P, Skrabut E, Yu LP, Coury A, Jarrett P,. Assay develoment and application for the determination of percent modification of divinyl sulfone modified hyaluronan hydrogel. In: Society for Biomaterials 2007 Annual Meeting, Chicago, IL, 2007.
31. Reed RK, Lilja K, Laurent TC,. Hyaluronan in the rat with special reference to the skin. Acta Physiol Scand 1988; 134: 405-411. (Pubitemid 18268552)
32. Raynaud J, Torrance G, Band P, Goldsmith C, Tugwell P, Walker V, Schultz M, Bellamy N,. A prospective, randomized pragmatic, health outcomes trial evaluating the incorporation of hylan G-F20 into the treatment paradigm for patients with knee osteoarthritis (part 1 of 2): Clincial results. Osteoarthritis Cartilage 2002: 506-517. (Pubitemid 34919065)
33. Wobig M, Dickhut A, Maier R, Vetter G,. Viscosupplementation with hylan G-F20: A 26-week controlled trial of efficacy and safety in the osteoarthritic knee. Clin Ther 1988: 410-423.
34. Caborn D, Rush J, Lanzer W, Parenti D, Murray C,. A randomized, single-blind comparison of the efficacy and tolerability of hylan G-F 20 and triamcinolone hexacetonide in patients with osteoarthritis of the knee. J Rheumatol 2004; 31: 333-343. (Pubitemid 38160757)
35. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV,. Efficacy of hylan G-F 20 and sodium hyaluronate in the treatment of osteoarthritis of the knee-A prospective randomized clinical trial. Knee 2008; 15: 318-324.